Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel S Merseburger

Showing results (221-230 of 323) with videos related to

Pageof 33
Sort By:
European Urology|April 25, 2006
MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsiesAristotelis G Anastasiadis, Matthias P Lichy, Udo Nagele, et al.
Advances in Therapy|September 21, 2018
Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC)André P Nicklas, Mario W Kramer, Jürgen Serth, et al.
Cell Communication and Signaling : CCS|February 15, 2024
Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cellsVijay Kumar Boddu, Piet Zamzow, Mario Wolfgang Kramer, et al.
British Journal of Cancer|October 3, 2022
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patientsLourdes Mengual, Maria Frantzi, Marika Mokou, et al.
The Lancet. Oncology|October 20, 2022
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b studyAxel S Merseburger, Gerhardt Attard, Lennart Åström, et al.
International Journal of Cancer|July 5, 2019
Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancerFinn Becker, Vincent Joerg, Marie C Hupe, et al.
BMC Cancer|February 23, 2020
Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancerMarie C Hupe, Lukas Dormayer, Tomasz Ozimek, et al.
Frontiers in Oncology|June 13, 2020
Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy-Real-World Clinical Impressions and Comparative Review of the LiteratureChristian Fuhrmann, Julian P Struck, Philipp Ivanyi, et al.
European Urology|April 7, 2009
HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancerMario W Kramer, Roozbeh Golshani, Axel S Merseburger, et al.
Aktuelle Urologie|January 14, 2021
RLC score (R status, lymphovascular invasion, C-reactive protein) predicts survival following radical cystectomy for muscle-invasive bladder cancerJulian Peter Struck, Marie Christine Hupe, Annika Heinisch, et al.
Pageof 33

Showing results (221-230 of 323) with videos related to

Sort By:
Pageof 33
European Urology|April 25, 2006
MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsiesAristotelis G Anastasiadis, Matthias P Lichy, Udo Nagele, et al.
Advances in Therapy|September 21, 2018
Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC)André P Nicklas, Mario W Kramer, Jürgen Serth, et al.
Cell Communication and Signaling : CCS|February 15, 2024
Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cellsVijay Kumar Boddu, Piet Zamzow, Mario Wolfgang Kramer, et al.
British Journal of Cancer|October 3, 2022
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patientsLourdes Mengual, Maria Frantzi, Marika Mokou, et al.
The Lancet. Oncology|October 20, 2022
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b studyAxel S Merseburger, Gerhardt Attard, Lennart Åström, et al.
International Journal of Cancer|July 5, 2019
Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancerFinn Becker, Vincent Joerg, Marie C Hupe, et al.
BMC Cancer|February 23, 2020
Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancerMarie C Hupe, Lukas Dormayer, Tomasz Ozimek, et al.
Frontiers in Oncology|June 13, 2020
Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy-Real-World Clinical Impressions and Comparative Review of the LiteratureChristian Fuhrmann, Julian P Struck, Philipp Ivanyi, et al.
European Urology|April 7, 2009
HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancerMario W Kramer, Roozbeh Golshani, Axel S Merseburger, et al.
Aktuelle Urologie|January 14, 2021
RLC score (R status, lymphovascular invasion, C-reactive protein) predicts survival following radical cystectomy for muscle-invasive bladder cancerJulian Peter Struck, Marie Christine Hupe, Annika Heinisch, et al.
Pageof 33